John T. Callaghan

THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVE

Thorir D. Bjornsson, John T. Callaghan, Heidi J. Einolf et al. · Drug Metabolism and Disposition · 2003 · 781 citations

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update

Kristine R. Crews, Andrea Gaedigk, Henry M. Dunnenberger et al. · Clinical Pharmacology & Therapeutics · 2014 · 669 citations · Full text

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype

Kristine R. Crews, Andrea Gaedigk, Henry M. Dunnenberger et al. · Clinical Pharmacology & Therapeutics · 2011 · 367 citations · Full text

Codeine Therapy, Pharmacotherapy, Cytochrome P450 2D6 +16

Clinical Pharmacogenetics Implementation Consortium Guideline for <i>CYP2D6</i>, <i>OPRM1</i>, and <i>COMT</i> Genotypes and Select Opioid Therapy

Kristine R. Crews, Andrew A. Monte, Rachel Huddart et al. · Clinical Pharmacology & Therapeutics · 2021 · 366 citations · Full text

The Conduct of In Vitro and In Vivo Drug‐Drug Interaction Studies: A PhRMA Perspective

Thorir D. Bjornsson, John T. Callaghan, Heidi J. Einolf et al. · The Journal of Clinical Pharmacology · 2003 · 309 citations

Drug Interactions, Preclinical Drug Evaluation, Biochemistry +14